Ozempic Feet: Causes, Symptoms, Treatment & Prevention

Reviewed by the HyaluFlow Health Editorial Team | Published: July 18, 2026 | Last Updated: August 26, 2026

Quick Answer: “Ozempic feet” is an informal term for foot changes noticed after substantial weight loss while using GLP-1 medicines such as semaglutide or tirzepatide. It is not an established diagnosis or recognized direct side effect. Reported changes may relate to reduced soft-tissue volume, body-composition changes, or altered foot mechanics.

Key Takeaways

“Ozempic feet” is not an official medical diagnosis.
Major weight loss can reduce soft-tissue fullness around the feet.
Changes in heel and forefoot cushioning may affect comfort.
Weight loss can also reduce lean mass, although effects on foot muscles are poorly studied.
Supportive footwear, adequate nutrition, and resistance training can support foot function.
Persistent pain, numbness, wounds, or swelling need medical evaluation.

What Is “Ozempic Feet”?

“Ozempic feet” is a social-media and clinical shorthand for changes some people notice in their feet after substantial weight loss while taking GLP-1 medicines.

People may report less fullness, more visible veins or tendons, different shoe fit, or discomfort while standing and walking. However, no large clinical trials have established “Ozempic feet” as a distinct medical condition.

Current evidence supports substantial weight and body-composition changes with GLP-1 treatment, but not direct medication-related damage to foot tissues.

Why Might Weight Loss Affect Your Feet?

The feet contain specialized soft tissues that help absorb and distribute forces during standing and walking. Heel and forefoot fat pads are particularly important for cushioning.

Research has associated plantar fat-pad structure with foot pain. A case-control study, Relationship Between Decreased Subcalcaneal Fat Pad Thickness and Plantar Heel Pain, found thinner subcalcaneal fat pads in people with unilateral heel pain.

This does not prove that GLP-1-related weight loss thins foot fat pads. It simply provides a plausible reason why changes in cushioning could affect comfort in some people.

GLP-1 Treatment and Body Composition

Weight loss does not come entirely from fat. Lean mass can also decline during substantial weight loss.

A DXA-based SURMOUNT-1 substudy found that tirzepatide reduced both fat and lean mass over 72 weeks, with about 75% of weight lost coming from fat and 25% from lean mass. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study

That finding does not show that GLP-1 treatment specifically causes muscle loss in the feet. Direct research on “Ozempic feet” remains limited.

What Might It Look or Feel Like?

Reported changes include less fullness, more visible veins or tendons, altered shoe fit, or soreness beneath the heel or forefoot.

Reported Change	Possible Explanation
Less fullness	Reduced soft-tissue volume
More visible structures	Less tissue covering veins, tendons, and bones
Heel discomfort	Multiple possible causes, including altered cushioning
Different shoe fit	Changes in foot soft-tissue volume
Walking discomfort	Biomechanical adaptation or another foot condition

These symptoms are not specific to GLP-1 medicines. Plantar fasciitis, arthritis, injuries, footwear, aging, activity changes, and nerve problems can cause similar symptoms.

What the Science Says

GLP-1 therapies can produce substantial weight loss. In the SELECT trial, semaglutide reduced cardiovascular events in adults with overweight or obesity and established cardiovascular disease without diabetes. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, New England Journal of Medicine

Research also supports the role of heel fat-pad structure in foot mechanics. Changes in functional characteristics of heel fat pad with age examines how soft-tissue characteristics and loading change with age.

Evidence Strength Summary

High: GLP-1 therapies can produce substantial weight loss.
High: Weight loss can reduce both fat and lean mass.
Moderate: Plantar soft-tissue characteristics affect foot mechanics.
Limited: Direct evidence linking GLP-1 therapy to “Ozempic feet” is lacking.

How to Protect Your Feet

There is no proven treatment specifically for “Ozempic feet.” The practical goal is to protect comfort and mobility while your body adapts.

Wear properly fitted shoes with adequate cushioning and stability.
Replace footwear that becomes loose or causes pressure points.
Maintain adequate protein intake for your individual needs.
Use resistance training to support lean-mass preservation.
Increase walking and exercise gradually.
Check your feet for blisters, redness, calluses, or skin breakdown.

People with diabetes or reduced sensation need especially careful foot care. The International Working Group on the Diabetic Foot prevention guideline recommends structured preventive care for people at risk of diabetic foot complications.

Common Myths

Myth: Ozempic directly damages the feet.

Fact: There is no established evidence that semaglutide directly damages foot tissues. Reported changes may instead reflect weight and body-composition changes.

Myth: Everyone taking GLP-1 drugs develops it.

Fact: Its prevalence is unknown because the phenomenon has not been formally defined or systematically studied.

Myth: Any foot pain during weight loss is “Ozempic feet.”

Fact: Foot pain has many possible causes and should not automatically be blamed on medication.

Myth: Stop your medication if your feet change.

Fact: Do not stop prescribed GLP-1 treatment without discussing new symptoms with your healthcare professional.

Who Should Pay Attention?

People with diabetes, neuropathy, circulation problems, existing foot disorders, or previous foot ulcers should take new symptoms seriously.

Seek medical evaluation for persistent pain, numbness, tingling, swelling, redness, open wounds, or difficulty walking rather than assuming these symptoms are simply caused by weight loss.

Bottom Line

“Ozempic feet” is an emerging term, not a confirmed medical condition or established direct side effect of GLP-1 medicines. Significant weight loss can change soft-tissue volume, body composition, and biomechanics, which may explain some reported changes.

There is not enough evidence to conclude that GLP-1 drugs cause plantar fat-pad loss or foot damage. Supportive footwear, adequate nutrition, strength training, and appropriate medical evaluation are more useful than assuming the medication is responsible.

Routine Inquiries & Guides

What are Ozempic feet?

Ozempic feet is an informal term describing changes in the appearance or comfort of the feet after significant weight loss with GLP-1 medications such as Ozempic® (semaglutide), Wegovy®, Mounjaro® (tirzepatide), and Zepbound®. It is not an officially recognized medical diagnosis or listed medication side effect. Current evidence suggests these changes are primarily caused by rapid fat loss, reduced lean muscle mass, and skin laxity rather than the medication directly affecting the feet.

Is Ozempic feet a real side effect?

No. Ozempic feet is not an official side effect listed by the U.S. Food and Drug Administration (FDA) or medication manufacturers. The term describes physical changes that some people experience after rapid weight loss while taking GLP-1 medications. Healthcare professionals believe these changes are related to body composition changes during weight loss rather than direct medication toxicity.

Can Ozempic cause foot pain?

Yes. Some people may develop foot pain during significant weight loss while taking Ozempic or other GLP-1 medications. As protective fat pads beneath the heel and forefoot become thinner, pressure on bones and joints may increase, leading to heel pain, discomfort under the ball of the foot (metatarsalgia), or soreness during prolonged standing or walking. Persistent or severe pain should be evaluated by a healthcare professional.

Does Ozempic make your feet smaller?

It can. Significant weight loss may reduce fat tissue throughout the body, including the feet. As swelling and soft tissue decrease, some people notice their feet become narrower or require a smaller shoe size. This change results from weight loss rather than a direct effect of Ozempic, Wegovy, Mounjaro, or Zepbound on the bones of the feet.

Is Ozempic feet permanent?

Not necessarily. Cosmetic changes such as visible veins or reduced fullness may improve as your weight stabilizes and your body adapts over time, although some changes can persist after substantial weight loss. If foot pain results from reduced cushioning, supportive footwear, cushioned insoles, strength training, and proper nutrition often help improve comfort. Individual results vary depending on age, skin elasticity, and the amount of weight lost.

Who is most likely to develop Ozempic feet?

People most likely to notice Ozempic feet include those who lose a large amount of weight rapidly, older adults with naturally thinner plantar fat pads, individuals with diabetes, people with existing foot conditions such as plantar fasciitis or arthritis, and those who consume insufficient protein or perform little resistance training during weight loss. However, not everyone taking GLP-1 medications experiences these changes.

Can Ozempic feet be prevented?

There is no guaranteed way to prevent Ozempic feet, but the risk may be reduced by following your prescribed GLP-1 dosing schedule, consuming adequate protein, performing regular resistance training, wearing supportive footwear, replacing shoes if your foot size changes, and monitoring your feet for new symptoms. Maintaining lean muscle mass during weight loss appears especially important for preserving foot function.

When should you see a doctor for Ozempic feet?

You should seek medical advice if you develop persistent foot pain, numbness, tingling, swelling, redness, open sores, ulcers, signs of infection, or difficulty walking. People with diabetes should promptly report any new foot changes because early evaluation can help prevent serious complications such as ulcers or infections.